Diabetes management in the new millennium using insulin pump therapyBruce W Bode
Atlanta Diabetes Associates, 77 Collier Road, NW, Suite 2080, Atlanta, GA 30309, USA
Diabetes Metab Res Rev 18:S14-20. 2002
..The recent introduction of methods for continuous glucose monitoring provides a new means to optimize the basal and bolus capabilities of CSII and offers the hope of the development of a feedback-controlled artificial pancreas...
- Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy
Bruce W Bode
Atlanta Diabetes Associates and Piedmont Hospital, Atlanta, Georgia, USA
Endocr Pract 10:71-80. 2004
..Hospitals should develop procedures to make IV insulin infusion therapy available to all appropriate patients...
- Glucommander: a computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation
Paul C Davidson
Atlanta Diabetes Associates, Suite 2080, Atlanta, GA 30309, USA
Diabetes Care 28:2418-23. 2005
..The published methods for administering the insulin are complex and are usually limited to intensive care units with a low patient-to-nurse ratio...
- Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system
Bruce W Bode
Atlanta Diabetes Associates, Atlanta, Georgia 30319, USA
Endocr Pract 11:157-64. 2005
..The recommended dose of insulin glargine after the switch in treatment is equal to the total daily basal dose on CSII...
- Demonstrations and discussions of continuous glucose monitors
Bruce W Bode
FACE, Atlanta Diabetes Association, Atlanta, Georgia 30309, USA
Diabetes Technol Ther 7:805-8. 2005
An overview of the pharmacokinetics, efficacy and safety of liraglutideBruce Bode
Atlanta Diabetes Associates, 77 Collier Rd, Suite 2080, Atlanta, GA 30309, USA
Diabetes Res Clin Pract 97:27-42. 2012
..The aim of this review is to assess the pharmacokinetics, efficacy and safety of the phase 3 data...
- Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge
Bruce Bode
Atlanta Diabetes Associates, Atlanta, GA 30309, USA
Hosp Pract (1995) 37:7-21. 2009
..This review examines the challenges to achieving glycemic control in the hospital setting and summarizes clinical data on the efficacy and safety of incretin-based therapies in their use in the hospital and after discharge...
- Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes
B W Bode
Atlanta Diabetes Associates, Georgia 30309, USA
Diabetes Care 24:69-72. 2001
....
- Intensive insulin therapy and insulin pumps
Bruce W Bode
Diabetes Resource Center, Piedmont Hospital in Atlanta, GA, USA
Postgrad Med 112:17-21. 2002
..Selecting the most appropriate insulin regimen and delivery system for patients' individual needs can help patients make a smoother transition to intensive insulin therapy and improve the likelihood of long-term success...
- Defining the importance of daily glycemic control and implications for type 2 diabetes management
Bruce W Bode
Atlanta Diabetes Associates, Atlanta, GA 30309, USA
Postgrad Med 121:82-93. 2009
..Dipeptidyl peptidase-4 inhibitors have the potential to play a vital role in diabetes management at all stages of the disease...
Insulin pump use in type 2 diabetesBruce W Bode
Atlanta Diabetes Associates, 77 Collier Road, Atlanta, GA 30309, USA
Diabetes Technol Ther 12:S17-21. 2010
..CSII may be appropriate for some people with T2DM, especially those for whom MDI therapy has failed...
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
B W Bode
Atlanta Diabetes Associates, Atlanta, GA, USA
Diabetes Obes Metab 12:604-12. 2010
....
- Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine
Bruce W Bode
Atlanta Diabetes Associates, Atlanta, Georgia, USA
Endocr Pract 17:271-80. 2011
....
- Liraglutide: a review of the first once-daily GLP-1 receptor agonist
Bruce Bode
Atlanta Diabetes Associates, 77 Collier Rd, Ste 2080, Atlanta, GA 30309, USA
Am J Manag Care 17:S59-70. 2011
..The guidelines prefer GLP-1 agonists over DPP-4 inhibitors because of their actions that promote weight loss and their somewhat greater effectiveness in reducing postprandial glucose excursions...
- Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies
Bruce W Bode
Atlanta Diabetes Associates, Georgia, USA
Am J Geriatr Pharmacother 9:423-33. 2011
..Managing elderly patients with type 2 diabetes poses particular challenges, so it is important to evaluate the efficacy and tolerability profile of antidiabetic therapies specifically in this patient population...
- What's ahead in glucose monitoring? New techniques hold promise for improved ease and accuracy
B W Bode
Diabetes Resource Center, Atlanta Diabetes Associates, 77 Collier Rd NW, Suite 2080, Atlanta, GA 30309, USA
Postgrad Med 109:41-4, 47-9. 2001
..By combining continuous glucose monitoring data with continuous insulin delivery via an external or an implantable insulin pump, the outlook promises to be much brighter for patients with type 1 diabetes...
- Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes
Bruce W Bode
Diabetes Resource Center, Atlanta Diabetes Associates, 77 Collier Rd NW, Suite 2080, Atlanta, GA 30309, USA
Postgrad Med 111:69-77; quiz 27. 2002
..Careful adjustment of basal and bolus doses and close follow-up, including patient education, are vital to the success of CSII...
- Patient perception and use of an insulin injector/glucose monitor combined device
Bruce Bode
Atlanta Diabetes Associates, 77 Collier Road NW, Suite 2080, Atlanta, GA 30309, USA
Diabetes Educ 30:301-9. 2004
..This clinical trial assessed patient preference, satisfaction, and use of an insulin injector/glucose monitor combination device versus syringes and a separate glucose monitor...
- Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections
Bruce W Bode
Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
Clin Ther 29:S135-44. 2007
..The 2 main methods of achieving this goal are continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDIs) comprising basal and prandial injections...
- Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio
Paul C Davidson
Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
Endocr Pract 14:1095-101. 2008
..To analyze and compare the underlying mathematical models for basal-bolus insulin-dosing guidelines in patients with type 1 diabetes in a retrospective controlled study...
- Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values
Bruce W Bode
Atlanta Diabetes Associates, Georgia, USA
Diabetes Care 28:2361-6. 2005
....
- Continuous glucose monitoring and intensive treatment of type 1 diabetes
William V Tamborlane
N Engl J Med 359:1464-76. 2008
..Further work is needed to identify barriers to effectiveness of continuous monitoring in children and adolescents. (ClinicalTrials.gov number, NCT00406133.)..
- Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study
Philip Raskin
University of Texas, Southwestern Medical Center, Dallas, Texas 75390 8858, USA
Diabetes Care 26:2598-603. 2003
..Compare the efficacy, safety, and patient satisfaction of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy for patients with type 2 diabetes...
- Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study
Irl B Hirsch
University of Washington Medical Center Roosevelt, Seattle, Washington 98105, USA
Diabetes Technol Ther 10:377-83. 2008
....
- Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII
Irl B Hirsch
University of Washington, Seattle, WA, USA
Diabetes Care 28:533-8. 2005
..Multiple daily injection (MDI) therapy of bolus insulin aspart and basal insulin glargine was compared with continuous subcutaneous insulin infusion (CSII) with aspart in type 1 diabetic patients previously treated with CSII...
- The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes
John Mastrototaro
Medtronic Diabetes, Northridge, California 91325 1219, USA
Diabetes Technol Ther 10:385-90. 2008
..The accuracy and efficacy of the Medtronic Diabetes (Northridge, CA) Real-Time (RT)-Continuous Glucose Monitoring (CGM) sensor were analyzed in 72 subjects with type 1 diabetes...
- Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial
Ralph A DeFronzo
University of Texas Health Science Center, Diabetes Division, 7703 Floyd Curl Dr, San Antonio, TX 78284, USA
Diabetes Care 28:1922-8. 2005
..This study investigates whether inhaled insulin (INH; Exubera) can achieve target glycemic control in patients failing on diet and exercise...
- Working to improve care of hospital hyperglycemia through statewide collaboration: the Georgia Hospital Association Diabetes Special Interest Group
Curtiss B Cook
Division of Endocrinology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
Endocr Pract 13:45-50. 2007
..To review the efforts of the Georgia Hospital Association Diabetes Special Interest Group (DSIG) to develop and disseminate sample clinical guidelines on management of inpatient hyperglycemia...
